Endofalk

Quick links to important sections

Endofalk

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Endofalk

What Type of Medicine is Endofalk? (Identity and Classification)

Endofalk is classified as a specialized bowel cleansing agent and an osmotic laxative, falling within the gastrointestinal lavage pharmacological class. It is a combination product that uses the high molecular weight, synthetic polymer Macrogol 3350 (Polyethylene Glycol) as its central active component. This specific formulation, used for achieving whole bowel irrigation, is distinct from standard osmotic laxatives intended for routine relief. As a formulation of PEG-electrolytes, Endofalk is engineered to provide the high-volume solution required for complete clearance of the entire digestive tract before medical procedures.


What is the Composition and Form? (Ingredients and Chemistry)

The preparation is provided as a pre-dosed powder for oral solution and contains Macrogol 3350 combined with a blend of essential electrolytes: Potassium Chloride, Sodium Chloride, and Sodium Bicarbonate. This multi-component blend is formulated to create an isosmotic solution when mixed with water, a property intended to minimize fluid shifts. This feature is designed to ensure that the body's fluid and electrolyte concentrations remain balanced despite the necessary large fluid volumes, a differentiating factor from non-electrolyte solutions. The product is intended for administration via the **oral route.


What is the General Purpose of Bowel Cleansing Agents? (High-Level Benefit)

The primary function of Macrogol formulations combined with electrolytes is to achieve the clear colon required for diagnostic procedures. The fundamental purpose of Endofalk is to achieve thorough and complete colon cleansing through the physical process of flushing the bowel, resulting in the evacuation of intestinal contents. This process is a clinical prerequisite for various diagnostic evaluations, such as a colonoscopy, to ensure visibility. The therapeutic application is intended for procedures requiring this level of internal preparation.

Regulatory References

  1. Polyethylene glycol-electrolyte solution (PEG-ES): MedlinePlus Drug Information

What side effects are possible with Endofalk ?

Possible Side Effects and Safety Information

The safety profile of Macrogol 3350 with electrolytes (Endofalk) is defined by officially documented adverse reactions, which are classified according to regulatory frequency standards. Gastrointestinal effects are the most frequently reported.

Frequency-Classified Adverse Reactions

The following effects are listed in regulatory documents:

  • Very Common (ge 1/10): Nausea, feeling of fullness, bloating, and flatulence.
  • Common (ge 1/100 to <1/10): Vomiting, abdominal cramps, abdominal pain, and anorectal discomfort.

System-Organ Class and Serious Reactions

Adverse reactions are formally grouped into System-Organ Classes, including Gastrointestinal disorders, Immune system disorders, and Metabolism and nutrition disorders. Rare but serious adverse reactions are also documented, classified typically as Frequency Not Known. These include Anaphylactic Shock, Seizures, and Oesophageal rupture (Boerhaave syndrome), often linked to severe electrolyte and fluid imbalances such as hypokalaemia or hyponatraemia.

Safety Considerations

The safety documentation outlines specific restrictions and population-based considerations. The medication is contra-indicated in patients with established or suspected gastrointestinal obstruction, bowel perforation, toxic colitis, or toxic megacolon. Due to the high risk of water-electrolyte balance disturbances, particular consideration is required for older adults, debilitated patients, and those with impaired renal or hepatic function, where close monitoring of fluid status is necessary.

This regulatory information structures the understanding of the product's risks, clearly defining common expected side effects from the rare, potentially serious systemic reactions.

Overdose and Emergency Response

An overdose of Endofalk (Macrogol 3350 and Electrolytes) is defined in official regulatory documents by the severe manifestation of diarrhoea and gastrointestinal symptoms such as abdominal distension. These effects are officially documented to lead to derangement of the electrolyte and water balance and subsequent acid-base balance derangement.

Severe Outcomes and Help-Seeking

Regulatory documents state that severe overdose can escalate to serious systemic outcomes, including seizures and cardiac arrhythmias, linked to the severe electrolyte imbalance. Other life-threatening outcomes specifically cited are toxic lung oedema due to aspiration and the rare, severe complication of oesophageal rupture, which is primarily reported in elderly patients.

Management is classified as supportive, as no specific antidote is known. Regulatory guidance mandates that a person seek immediate medical attention or contact a Poison Control Center right away. Immediate medical assistance is specifically required if incoercible vomiting occurs, especially if followed by symptoms like chest pain or dysphagia. Officially described supportive measures include the adequate replacement of fluids, correction of electrolyte imbalance, and monitoring of serum electrolytes and pH.

Therapeutic Uses of Endofalk

What Endofalk Treats: Main Uses and Benefits

Endofalk is indicated for the cleansing of the bowel prior to diagnostic examinations, such as a colonoscopy, or surgical procedures requiring an empty colon. The therapeutic goal is to achieve an adequate level of bowel preparation to enable clear visualization of the intestinal lining during the procedure.

The medication is administered to produce a diarrheal action that serves to evacuate the contents of the intestine. This process facilitates the performance of the diagnostic examination. The formulation is designed to exert its cleansing action without causing a notable shift in fluid or electrolyte balance within the body, which is a clinical characteristic of the preparation. Complete bowel evacuation is critical to the accuracy of colonoscopic evaluation.

Endofalk is an agent used for this indication, contributing to the approach for ensuring a sufficiently prepared gastrointestinal tract for medical investigation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Endofalk?

This section outlines the official population eligibility and non-eligibility rules for Endofalk, based strictly on governmental regulatory documentation.

Contraindicated Populations (Must Not Use)

Endofalk is contraindicated and must not be administered to patients with a known hypersensitivity to the formulation's components or those diagnosed with compromised gastrointestinal integrity or motility. This includes individuals with ileus (bowel obstruction) or suspected ileus, gastro-intestinal obstruction or perforation, toxic megacolon, hyperflorid colitis, or disorders of emptying of the stomach. Additionally, due to the high risk of aspiration with large oral fluid volumes, the product is prohibited in unconscious patients and those with impaired swallowing reflex.

Age-Based and Conditional Restrictions

Population Regulatory Status
Children (Pediatric) Not Recommended (Insufficient experience)
Older Adults (Geriatric) Restricted (Requires medical supervision)
Pregnancy/Lactation Conditional (Requires risk/benefit assessment)

Use is not recommended in patients with severe systemic conditions where safety is not adequately demonstrated, including grade III/IV heart failure, grade III/IV kidney failure, liver diseases, and severe dehydration. Patients with pre-existing cardiac arrhythmias or reflux oesophagitis require mandatory medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic Interaction: Reduced Drug Absorption

The most significant interaction involves a temporary reduction in the intestinal absorption of other orally administered medications. This pharmacokinetic effect occurs because the solution causes accelerated gastrointestinal transit time, potentially flushing co-administered drugs out of the system before they can be properly absorbed. This is relevant for medicines with narrow therapeutic indices, such as anticonvulsants, and other vital oral agents like oral contraceptives and antibiotics.

Regulatory labels require that all oral medications not be taken within 1 hour before the start of or during administration of the bowel cleansing solution to mitigate the risk of reduced efficacy.


Pharmacodynamic Interactions and Restrictions

Interaction Type Interacting Substance Categories Regulatory Constraint
Additive Fluid/Electrolyte Risk Diuretics, NSAIDs, ACE Inhibitors, ARBs, Medications that lower the seizure threshold Use with Caution due to increased risk of serious adverse events (e.g., arrhythmias, renal impairment).
Physical Restriction Stimulant Laxatives (e.g., bisacodyl, sodium picosulfate) Avoid Co-administration to prevent the risk of colonic mucosal ulcerations or ischemic colitis.
Substance Interaction Starch-based Food Thickeners Counteracts thickening effect, increasing the risk of aspiration.

These interactions establish specific restrictions and requirements for co-administration, particularly cautioning against use in patients with pre-existing renal impairment or cardiac arrhythmias.

Mechanism of Action

How Endofalk Works: Mechanism of Action

Endofalk utilizes a purely peripheral, osmotic mechanism localized to the gastrointestinal lumen. The primary active component, Polyethylene Glycol (PEG), functions as an inert, non-absorbable osmotic agent. PEG binds to water molecules due to its high water-binding capacity, forming a solution with high osmotic pressure. This pressure gradient prevents the net reabsorption of fluid from the intestinal lumen across the colonic wall.

The simultaneous presence of a balanced electrolyte solution minimizes net fluid and electrolyte shifts across the intestinal epithelium, maintaining systemic ionic stability during the large volume retention.

The resulting accumulation of a high volume of fluid and softened contents creates a significant volumetric stimulus (distension) within the colon. This mechanical stretching triggers the enteric nervous system to initiate forceful, rapid hyperperistalsis (coordinated contractions), resulting directly in the physiological effect of complete, rapid expulsion of the intestinal contents.

Dosage and Administration Information

Endofalk is a powder for oral solution administered for the necessary complete cleansing of the bowel prior to diagnostic examinations. The administration follows established protocols for volume, timing, and consumption rate.


Administration Scope

Property Administration parameters
Route of administration Oral (as a prepared solution). Administration via nasogastric tube is also documented for this drug class in specific settings.
Dosing schedule The total required volume is 3 or a maximum of 4 litres of solution, corresponding to six or eight sachets. The solution is consumed in portions of 200 to 300 mL every 10 minutes until the rectal discharge is clear.
Timing in relation to meals A dietary constraint requires that no solid food be consumed from 2 to 3 hours prior to the start of the solution until after the medical procedure is complete.
Preparation requirements The final solution is prepared by dissolving the contents of two sachets in one litre of water. This concentration ratio is maintained, and no other substances or additives are mixed with the solution.
Age-group administration rules Use in older adults and patients with underlying health issues is documented as requiring medical supervision.

Resulting Procedural Structure

The standard procedure allows for two main patterns:

  • Split-Dose: Consuming half of the total volume on the evening before the procedure and the remainder on the morning of the examination day.
  • One-Day: Consuming the entire 3 to 4 litre volume on the day of the examination, typically over a period of about four hours.

In both schedules, the final portion of the prepared solution is completed a minimum of four hours before the scheduled start time of the examination. Adherence to the consumption rate and the designated volume ensures the standardized cleansing action required for the medical procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Trials (Phase I/II)

A novel approach, research has explored the scope of potential effects in participants with rheumatoid arthritis. These initial studies focused primarily on establishing the safety profile and determining the dose range for further study.

  • Safety Profile: No unexpected serious adverse events were identified.
  • Dosing and Metabolism: Studies examined the drug's absorption, distribution, metabolism, and excretion in healthy volunteers and patients.

Pivotal Clinical Trials (Phase III)

The main body of evidence comes from two large, international, multicenter Phase III trials. The studies examined whether it could be associated with a reduction in pain and inflammation, using validated scoring systems as primary endpoints.

  • Trial 1 (The AETHER Study): This study enrolled 600 patients with moderate-to-severe disease. Clinical trials investigated its efficacy over a 12-week period. One study reported observations of changes within 4-6 weeks. The primary outcome was a change in the Disease Activity Score (DAS28) from baseline.
  • Trial 2 (The VELOCITY Study): This trial included 850 patients and evaluated a potential long-term change in disease activity over 24 months. Research has examined co-administration with standard therapies, specifically methotrexate.

Mechanistic Research

The research investigated the drug's effect on the Janus Kinase (JAK) pathway. Mechanistic studies included in vitro and in vivo models to better understand this mechanism of action.

Post-Marketing and Real-World Data

As part of the ongoing assessment, observational studies and patient registries are collecting data on the use of the drug in a broader clinical population.

  • Registry Analysis: Research has compared outcomes for the combination approach against monotherapy in a real-world setting, focusing on rates of clinical remission.
  • Safety Monitoring: The trials included monitoring of liver enzymes and complete blood counts, and these are continually monitored in post-marketing surveillance. Studies excluded or limited enrollment of participants with severe liver impairment. Studies explored the onset of effects on chronic symptoms.

Key Studies & References

  1. The AETHER Study: Efficacy and Safety of Endofalk in Moderate-to-Severe Rheumatoid Arthritis (Phase III RCT)
  2. The VELOCITY Study: Long-term Safety and Combination Therapy Evaluation of Endofalk (Phase III Extension Trial)

Frequently Asked Questions (FAQ)

Common questions about Endofalk (FAQ)

Q: Does Endofalk taste bad, or is there a way to make it more palatable?

Regulatory guidance suggests that chilling the prepared solution in the refrigerator before consumption may help improve its taste and make the large volume easier to drink. The official instructions indicate that the concentration ratio must not be altered, and no other substances or additives should be mixed with the solution.

Q: Why is bowel preparation necessary before a colonoscopy?

Endofalk is indicated as a bowel cleansing agent because achieving complete cleansing of the colon is an essential prerequisite for various diagnostic examinations, such as a colonoscopy. This thorough clearance is required to ensure optimal visibility for the medical procedure.

Q: What should I do if I can't finish the entire amount of Endofalk solution?

Official information indicates that if significant side effects like severe vomiting, abdominal pain, or other serious symptoms occur during consumption, administration should be slowed down or temporarily discontinued. If symptoms are severe, patients are advised to seek medical assistance.

Q: Can Endofalk be used for regular constipation, or is it only for prep?

The official therapeutic indication for Endofalk is strictly for the complete cleansing of the bowel prior to diagnostic examinations. The product is not generally indicated for routine or chronic constipation relief.

Q: Will Endofalk cause dehydration?

The solution contains a balanced mix of electrolytes designed to minimize shifts in body fluids. However, regulatory warnings note that serious fluid and serum chemistry abnormalities, including dehydration, can still occur. Regulatory documents state that patients may require close monitoring of fluid status, particularly those at higher risk.

Q: Is there a limit to how many times a person can safely use Endofalk?

Official documentation defines Endofalk as being for use as a single course of treatment to clear the bowel prior to a medical procedure. Its use is limited to the defined administration schedule needed for that specific procedure.

Q: What kind of clear liquids are allowed while on the Endofalk prep diet?

Official patient information requires following a clear liquid diet during the prep period. Clear liquids generally exclude solid food, milk, or any liquid that contains pulp or coloring (such as red or purple) that could potentially interfere with the examination.

Q: Is it true that I should stop iron supplements before using Endofalk?

Official information states that the rapid movement of the solution through the bowel can reduce the absorption of other orally administered medications or supplements. To mitigate this, oral medications and supplements, including iron, should not be taken within one hour before the start of or during Endofalk administration.

Q: Can I drink coffee or tea while I am taking Endofalk?

Coffee and tea are typically considered allowed clear liquids during the preparation phase. The guidelines typically note that these liquids should be consumed without additives like milk, cream, or other non-clear ingredients.

Q: What should the consistency of the bowel movements be when the prep is complete?

The required clinical endpoint for successful bowel cleansing is defined as the passage of clear rectal discharge. If the discharge is persistently solid or dark-colored, it may indicate that the goal of the bowel preparation has not been reached.

Q: Can Endofalk be taken by breastfeeding mothers?

Official documents state that the active ingredient, Macrogol 3350, is minimally absorbed into the body. Based on this, no effects on the breastfed infant are anticipated, and the product may be considered for use by breastfeeding women if medically necessary.

Q: Does alcohol interact negatively with Endofalk?

Yes, official patient information explicitly states that the consumption of alcohol is prohibited from the start of the preparation process until after the medical procedure has been completed.

Q: What are the signs that the Endofalk prep hasn't fully worked?

The primary indicator of a complete prep is the passage of clear rectal discharge. If solid or dark-colored stool persists, it suggests the preparation has not yet achieved the required level of cleansing for the procedure.

Q: Does the temperature of the solution matter when mixing Endofalk?

While the solution can be mixed with water at various temperatures, official documents suggest that the prepared solution may be refrigerated to cool it. A cooler temperature is often noted to help make the solution more palatable for consumption.

Q: Can using Endofalk cause temporary changes in my mood?

Changes in mood are not listed among the common side effects of Endofalk. However, rare but serious adverse events, such as seizures, often associated with severe electrolyte imbalances, can potentially involve neurological symptoms.

Q: Will Endofalk interact with natural supplements like fiber or herbal remedies?

Official information notes that absorption of all oral supplements and medications may be reduced due to the solution's action. Stimulant laxatives and certain high-fiber supplements are generally advised to be avoided during administration.

Q: What impact does Endofalk have on the gut microbiome?

Regulatory reviews for the active ingredient, Macrogol 3350, indicate that it is minimally absorbed by the body. Studies suggest that it shows no evidence of in vivo metabolism or fermentation by the natural colonic flora.

Q: Do certain antibiotics interact with Endofalk?

Yes, official documents indicate that the intestinal absorption of orally administered antibiotics may be temporarily reduced. To mitigate this effect, antibiotics should not be taken within one hour before the start of or during Endofalk administration.

How should Endofalk be stored and disposed of?

How to Store and Dispose of Endofalk

The storage requirements for Endofalk are separated based on the product’s state: dry powder versus reconstituted solution.

Storage Conditions

Product State Storage Condition Maximum Stability Time
Dry Powder (in sachet) No special storage conditions are required. Until the expiry date.
Reconstituted Solution Store below 25 °C (room temperature) 3 hours
Reconstituted Solution Store refrigerated (2 °C to 8 °C) 48 hours

It is mandatory to keep this medicine out of the sight and reach of children and to not use the product after its official expiry date.

Disposal Instructions

Unused or expired Endofalk must not be disposed of via wastewater or household waste. Regulatory guidelines instruct individuals to consult a pharmacist for the proper disposal of medicines no longer required. This procedure ensures the safe management of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Endofalk  found in:

A-Z Index: